• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed

    1/19/21 9:42:44 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care
    Get the next $RELV alert in real time by email
    15-12G 1 relv20210115_1512g.htm FORM 15-12G relv20210115_1512g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES AND EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Commission File No. 000-19932

     

    RELIV INTERNATIONAL, INC.

    (Exact name of registrant as specified in its charter)

     

    136 Chesterfield Industrial Blvd.

    Chesterfield, Missouri 63005

    (636) 537-9715

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

      

    Common Stock $.001 par value

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty

    to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

     

    Rule 12g-4(a)(l)

    ☒

     

    Rule 12g-4(a)(2)

    ☐

     

    Rule 12h-3(b)(1)(i)

    ☒

     

    Rule 12h-3(b)(1)(ii)

    ☐

     

    Rule 15d-6

    ☐

     

    Rule 15d-22(b)

    ☐

     

    Approximate number of holders of record as of the certification or notice date:          27           

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Reliv International, Inc. has caused this Certification and Notice to be signed on its behalf by the undersigned duly authorized person.

     

           
               

     

     

     

     

    RELIV INTERNATIONAL, INC.

    Date:

    January 19, 2021

     

    By:

    /s/ Ryan A. Montgomery

     

     

     

    Name:

    Ryan A. Montgomery

     

     

     

    Title:

    Chief Executive Officer

     

     

     
    Get the next $RELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RELV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Reliv International, Inc. Announces Update to its Reverse Stock Split Transaction and Plan to Delist from NASDAQ and Deregister its Common Stock

    CHESTERFIELD, Mo., Dec. 4, 2020 /PRNewswire/ -- Reliv International, Inc. (NASDAQ:RELV), a developer and marketer of nutritional supplements that promote optimal health, today announced an update to its plan to suspend its obligations to file periodic and current reports and other information with the U.S. Securities and Exchange Commission (the "Commission") under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and to delist its common stock from trading on the NASDAQ Stock Exchange as previously announced in a press release on October 19, 2020. December 21, 2020 will be the effective date of the Company's 1-for-2,000 reverse stock split (the "Reverse Split") of its

    12/4/20 4:15:00 PM ET
    $RELV
    Major Pharmaceuticals
    Health Care

    $RELV
    SEC Filings

    View All

    SEC Form 15-12G filed

    15-12G - RELIV INTERNATIONAL INC (0000768710) (Filer)

    1/19/21 9:42:44 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13E3/A filed

    SC 13E3/A - RELIV INTERNATIONAL INC (0000768710) (Subject)

    1/19/21 9:32:57 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care

    SEC Form 8 filed

    8-K - RELIV INTERNATIONAL INC (0000768710) (Filer)

    12/23/20 11:34:31 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care